It’s only fair to share… ZASTAPRAZAN 2133852-18-1 362.5 g/mol, C22H26N4O JAQBO; JP-1366; OCN-101; Zastaprazan citrate – Onconic Therapeutics, UNII-W9S9KZX5MD Highest Development Phases Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases. SCHEME Patent WO2018008929 PATENT KR1777971 //////////ZASTAPRAZAN, JAQBO, JP-1366, OCN-101, Zastaprazan citrate, Onconic Therapeutics, …